Impact of immune checkpoint inhibitors on survival outcomes in advanced gastric cancer in Japan: A real-world analysis.

Toru KadonoSatoru IwasaToshiharu HiroseHidekazu HiranoNatsuko OkitaHirokazu ShojiAtsuo TakashimaKen Kato

Published in: Cancer medicine (2024)

The proportion of patients transitioning to third-line treatment and survival outcomes following progression on second-line treatment have improved since the approval of nivolumab. This drug might help to prolong overall survival in real-world practice.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
healthcare
emergency department
prognostic factors
lymph node
patient reported outcomes
drug induced
adverse drug
locally advanced